KARAM BIOSCIENCE
Multimodal cell-state panel
Public scope outline / 2026-10-15

Proposed research work, not an accepted engagement or demonstrated result.

STATUS
Proposed evaluation plan. No completed Karam result.

QUESTION
Can an agreed set of senescence, viability and functional readouts produce a more interpretable comparison than a marker considered alone?

RATIONALE
The source map proposes a partner-delivered Cell-State Panel. This project brief makes the commercial acceptance question explicit: will the panel produce a result a research customer can understand, reproduce and use to choose the next study? It is a validation plan, not a test menu or a claim that Karam already operates a laboratory.

WORK PACKAGES
Choose one use case: Specify the model, comparison and decision. Do not combine unrelated cell systems into one universal score.
Commission a complete scope: Obtain a qualified laboratory quote covering controls, repeat rules, data delivery and commercial-use rights.
Keep readouts separate: Preserve viability, marker and function results so discordance is visible instead of averaged away.
Review delivery quality: Assess reproducibility, failed runs, missing metadata and whether the final report resolves the original question.

DECISION GATE
Advance only when partner capacity, written rights, quality controls and an interpretable handover are established. A marker change accompanied by unexplained cell loss is a reason to investigate, not label a result rejuvenation.

PARTNER PROFILE
Established laboratories with relevant model experience, research customers with a specific comparison and reviewers able to interpret the chosen measurements.

NOT YET ESTABLISHED
No Karam assay validation, physical kit inventory, partner contract or clinical utility is claimed.